Mark Street-Docherty
Directeur Général chez Rosa Biotech Ltd.
Profil
Mark Street-Docherty is currently the Chief Executive Officer at Rosa Biotech Ltd.
He previously held the position of Chief Executive Officer at Delta Diagnostics (UK) Ltd.
from 2017 to 2020.
Postes actifs de Mark Street-Docherty
| Sociétés | Poste | Début |
|---|---|---|
Rosa Biotech Ltd.
 Rosa Biotech Ltd. Packaged SoftwareTechnology Services Rosa Biotech Ltd. is a British company that is redefining biosensing. The company is based in Bristol, UK. The company is focused on addressing intractable challenges in early disease diagnosis and industrial biotechnology. The company was founded in 2019. Mark Street-Docherty has been the CEO of the company since 2022. | Directeur Général | 01/06/2022 |
Anciens postes connus de Mark Street-Docherty
| Sociétés | Poste | Fin |
|---|---|---|
Delta Diagnostics (UK) Ltd.
 Delta Diagnostics (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom. | Directeur Général | 01/01/2020 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Delta Diagnostics (UK) Ltd.
Delta Diagnostics (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom. | Commercial Services |
Rosa Biotech Ltd.
Rosa Biotech Ltd. Packaged SoftwareTechnology Services Rosa Biotech Ltd. is a British company that is redefining biosensing. The company is based in Bristol, UK. The company is focused on addressing intractable challenges in early disease diagnosis and industrial biotechnology. The company was founded in 2019. Mark Street-Docherty has been the CEO of the company since 2022. | Technology Services |
